Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. covers the month of February 2020, specifically dated February 10, 2020. DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, with operations in the United States. The company focuses on developing Viaskin, an investigational proprietary technology platform based on epicutaneous immunotherapy (EPIT) for the treatment of food allergies and other immune diseases.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of an upcoming investor presentation and does not contain financial statements or quantitative performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document serves solely to announce a corporate event.
Guidance, Outlook, and Management Commentary
Management has announced that CEO Daniel Tassé and CFO Ramzi Benamar will present at the SVB Leerink 9th Annual Global Healthcare Conference on February 26, 2020. A live webcast and subsequent replay will be available on the company's investor relations website. The company continues its clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development of Viaskin Egg, and a human proof-of-concept study for Viaskin Milk in treating Eosinophilic Esophagitis.
Important Facts for Investors to Verify
- Confirm the date and time of the SVB Leerink conference presentation (February 26, 2020, 1:00 pm EST).
- Verify the availability of the live webcast and replay on the DBV Technologies investor relations website.
- Review the company's latest financial reports (Form 20-F) for actual financial metrics, as this filing contains none.
- Monitor updates on the clinical trial status of Viaskin Peanut, Viaskin Milk, and Viaskin Egg.